PRE Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 2.79
- P/S (TTM)
- 2.86
- EV/EBITDA
- 0.14
Profitability & growth
- ROE (TTM)
- -40.8%
- Operating margin
- -24.7%
- Revenue growth YoY
- 107.7%
- Dividend yield
- —
- Beta
- 0.24
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Prenetics Global Ltd
Company profilePrenetics Global Ltd (PRE) is a pioneering health technology company that specializes in cutting-edge genetic and diagnostic testing solutions, providing critical health insights to both consumers and healthcare professionals. With a strong emphasis on research and development, Prenetics has established a significant international presence through strategic partnerships and collaborations. As a leader in personalized medicine, the company is well-positioned to capitalize on the increasing demand for accessible and actionable health data, presenting a compelling investment opportunity in the…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- UNIT 703-706, K11 ATELIER KING?S ROAD, QUARRY BAY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer